Who Paid My Doc
Justin Tilan
Orthopaedic Trauma Saint Louis, MO Medical Doctor
NPI 1790195824 CMS profile 2192596
4921 Parkview Pl, Ste 6A/6B/12A, Saint Louis, MO 63110
General payments
$7,453
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Justin Tilan of Saint Louis, MO is reported in the CMS Open Payments database as having received $7,453 across 18 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 45th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $172 | 1 | |
| 2024 | General | $1,698 | 3 | |
| 2023 | General | $4,700 | 10 | |
| 2020 | General | $765 | 2 | |
| 2019 | General | $118 | 2 |
Beside peers
- Justin Tilan
- Orthopaedic Trauma median
- Middle half of Orthopaedic Trauma
- National median
In program year 2025, general payments to Justin Tilan were reported at $172. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.
Show as a table
| Year | Justin Tilan | Orthopaedic Trauma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $118 | $1,475 | $264–$6,401 | $163 |
| 2020 | $765 | $596 | $120–$4,020 | $114 |
| 2021 | $0 | $919 | $171–$4,697 | $132 |
| 2022 | $0 | $1,547 | $272–$7,240 | $149 |
| 2023 | $4,700 | $1,330 | $247–$5,875 | $160 |
| 2024 | $1,698 | $1,288 | $277–$6,797 | $164 |
| 2025 | $172 | $1,227 | $259–$7,433 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
272
Drug cost
$3,479
Branded share of claims
49.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 52 | $850 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 45 | $631 | |
| Naloxone Hcl | Generic | 11 | $541 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 13 | $358 | |
| Gabapentin | Generic | 40 | $324 | |
| Tramadol Hcl | Generic | 37 | $259 | |
| Meloxicam | Generic | 33 | $194 | |
| Oxycodone Hcl | Generic | 16 | $167 | |
| Ondansetron Odt Ondansetron | Brand | 25 | $155 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Trauma in Missouri
Related records
Orthopaedic Trauma in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Trauma
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.